References
- Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978; 75: 778–82
- Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med 2001; 161: 525–33
- Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002; 162: 2177–84
- LaMont JT. Bacterial infection of the colon. Textbook of gastoroenterology, T Yamada. Lippincott Williams & Wilkins, Philadelphia 2003; 1662
- Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile-associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004; 53: 673–7
- Lahatte LJ. Antibiotic-associated injury to the gut. In: Haubrich WS, Schaffner F, Berkin JE Bucks Gastroenterology. WB Saunders; 1985. p 1662.
- Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 199;4330:257–62.
- Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363–72
- Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004; 47: 1620–6
- Nomura K, Fukumoto K, Shimizu D, Okuda T, Yoshida N, Kamitsuji Y, et al. Pseudomembranous colitis presenting as acute colonic obstruction without diarrhea in a patient with gastric Burkitt lymphoma. World J Gastroenterol 2005; 11: 2681–3
- Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834–44
- Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 2007; 28: 932–40
- Nomura K, Morikawa N, Ikawa K, Ikeda K, Fujimoto Y, Shimizu D, , et al. Optimized dosage and method of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis J Antimicrob Chemother; In press.
- Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004; 171: 33–8
- Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007; 64: 2359–63
- Moshkowitz M, Ben-Baruch E, Kline Z, Shimoni Z, Niven M, Konikoff F. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis 2007; 9: 173–7
- Yamagiwa S, Yoshida Y, Halder RC, Weerasinghe A, Sugahara S, Asakura H, et al. Mechanisms involved in enteropathy induced by administration of non-steroidal antiinflammatory drugs (NSAIDS). Dig Dis Sci 2001; 46: 192–9
- Tsujimura H, Sakai C, Ishii A, Takagi T, Kumagai K. Fatal fulminant Clostridium difficile colitis during CHOP therapy for lymphoma: an autopsy case. Intern Med 2007; 46: 401–4